Identifying Equity Priorities for Xenotransplantation Human Clinical Trials

Prof. Kimberly and colleagues seek to explore the equity-related values, priorities, motivations, and understandings of people with end-stage kidney disease who are most likely to be eligible for xenotransplant clinical trial participation, the perspectives of their care partners, and of clinician-researchers who are positioned to influence trial design and participate in trial recruitment. This project aims to produce much-needed empirically grounded bioethics guidance to ensure equity considerations are incorporated proactively as xenotransplant human clinical trials are initiated.